On March 20, 2018 – Crescendo Biologics Limited (Crescendo), the drug developer of novel,
targeted T-cell engaging therapeutics, announces that Dr Brian McGuinness, Head of New Product and
Business Development, Phil Bland-Ward (CSO) and James Legg (VP R&D) will be presenting a poster at
AACR (American Association for Cancer Research) Annual Meeting in Chicago, USA on 18 April 2018 (Press release, Crescendo Biologics, MAR 20, 2018, View Source [SID1234525091]). The Crescendo team will be available to discuss the poster entitled "Multifunctional biologics for
targeted T-cell therapy based on in vivo matured fully human VH domains" within the "Antibodies,
Fusion Proteins and Related Biologics session". This will cover the beneficial characteristics of
Humabodies and their enhanced therapeutic potential over traditional monoclonal antibodies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster details
Title: Multifunctional biologics for targeted T-cell therapy based on in vivo matured fully human VH
domains
Authors: J. Legg, B. McGuinness, P. Bland-Ward, P. Pack
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibodies, Fusion Proteins, and Related Biologics
Session Date and Time: Wednesday Apr 18, 2018 8:00 AM – 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 35
Poster Board Number: 11
Permanent Abstract Number: 5766
There will also be a poster by Eleven Biotherapeutics in the same session which includes data from
Crescendo. This poster, entitled ‘Engineering and characterization of anti-PSMA humabody-deBouganin
fusion proteins’, will be at Board Number 15.
AACR’s Annual Meeting is being held in Chicago, Illinois from 14 – 18 April. The theme is ‘Driving
Innovative Cancer Science to Patient Care’. Presentations at the Annual Meeting will cover the latest
basic, translational, clinical, and prevention-focused research in the field, including important areas such
as early detection, cancer interception, and survivorship in all populations.